aTYR PHARMA INC Operating Expenses
aTYR PHARMA INC (ATYR) reported Operating Expenses of $10.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-07
- aTYR PHARMA INC operating expenses for the quarter ending 2026-06-30 was $10.88M, a 46.43% decline year-over-year.
- aTYR PHARMA INC operating expenses for the quarter ending 2026-03-31 was $11.44M, a 27.50% decline year-over-year.
- aTYR PHARMA INC operating expenses for the quarter ending 2025-12-31 was $14.80M, a 6.47% decline year-over-year.
- aTYR PHARMA INC operating expenses for the quarter ending 2025-09-30 was $26.93M, a 48.46% increase year-over-year.
- aTYR PHARMA INC operating expenses for fiscal 2025 was $77.82M, a 14.19% increase from fiscal 2024.
- aTYR PHARMA INC operating expenses for fiscal 2024 was $68.15M, a 23.30% increase from fiscal 2023.
- aTYR PHARMA INC operating expenses for fiscal 2023 was $55.27M, a 2.67% decline from fiscal 2022.
- aTYR PHARMA INC operating expenses for fiscal 2022 was $56.79M, a 66.96% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.88M 10-Q · filed 2026-08-07 | $22.32M 10-Q · filed 2026-08-07 | $37.11M derived: sum of 3 quarters · filed 2026-08-07 | $64.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $11.44M 10-Q · filed 2026-05-15 | $26.23M derived: sum of 2 quarters · filed 2026-05-15 | $53.17M derived: sum of 3 quarters · filed 2026-05-15 | $73.48M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $41.73M derived: sum of 2 quarters · filed 2026-03-05 | $62.04M derived: sum of 3 quarters · filed 2026-08-07 | $77.82M 10-K · filed 2026-03-05 |
| 2025-09-30 | $26.93M 10-Q · filed 2025-11-06 | $47.25M derived: sum of 2 quarters · filed 2026-08-07 | $63.02M 10-Q · filed 2025-11-06 | $78.84M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $20.31M 10-Q · filed 2026-08-07 | $36.09M 10-Q · filed 2026-08-07 | $51.91M derived: sum of 3 quarters · filed 2026-08-07 | $70.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $15.77M 10-Q · filed 2026-05-15 | $31.59M derived: sum of 2 quarters · filed 2026-05-15 | $49.74M derived: sum of 3 quarters · filed 2026-05-15 | $67.05M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $15.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $33.96M derived: sum of 2 quarters · filed 2026-03-05 | $51.28M derived: sum of 3 quarters · filed 2026-03-05 | $68.15M 10-K · filed 2026-03-05 |
| 2024-09-30 | $18.14M 10-Q · filed 2025-11-06 | $35.46M derived: sum of 2 quarters · filed 2025-11-06 | $52.33M 10-Q · filed 2025-11-06 | $68.29M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $17.32M 10-Q · filed 2025-08-07 | $34.19M 10-Q · filed 2025-08-07 | $50.15M derived: sum of 3 quarters · filed 2026-03-05 | $63.11M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $16.87M 10-Q · filed 2025-05-07 | $32.83M derived: sum of 2 quarters · filed 2026-03-05 | $45.80M derived: sum of 3 quarters · filed 2026-03-05 | $59.36M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $15.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.93M derived: sum of 2 quarters · filed 2026-03-05 | $42.48M derived: sum of 3 quarters · filed 2026-03-05 | $55.27M 10-K · filed 2026-03-05 |
| 2023-09-30 | $12.97M 10-Q · filed 2024-11-07 | $26.53M derived: sum of 2 quarters · filed 2024-11-07 | $39.31M 10-Q · filed 2024-11-07 | $57.65M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $13.56M 10-Q · filed 2024-08-13 | $26.34M 10-Q · filed 2024-08-13 | $44.68M derived: sum of 3 quarters · filed 2025-03-13 | $58.17M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $12.79M 10-Q · filed 2024-05-02 | $31.12M derived: sum of 2 quarters · filed 2025-03-13 | $44.62M derived: sum of 3 quarters · filed 2025-03-13 | $57.20M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $18.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $31.83M derived: sum of 2 quarters · filed 2025-03-13 | $44.41M derived: sum of 3 quarters · filed 2025-03-13 | $56.79M 10-K · filed 2025-03-13 |
| 2022-09-30 | $13.49M 10-Q · filed 2023-11-09 | $26.08M derived: sum of 2 quarters · filed 2023-11-09 | $38.45M 10-Q · filed 2023-11-09 | $47.09M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $12.58M 10-Q · filed 2023-08-09 | $24.96M 10-Q · filed 2023-08-09 | $33.60M derived: sum of 3 quarters · filed 2024-03-14 | $41.33M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $12.38M 10-Q · filed 2023-05-09 | $21.02M derived: sum of 2 quarters · filed 2024-03-14 | $28.75M derived: sum of 3 quarters · filed 2024-03-14 | $39.19M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $8.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $16.37M derived: sum of 2 quarters · filed 2024-03-14 | $26.81M derived: sum of 3 quarters · filed 2024-03-14 | $34.02M 10-K · filed 2024-03-14 |
| 2021-09-30 | $7.73M 10-Q · filed 2022-11-14 | $18.17M derived: sum of 2 quarters · filed 2022-11-14 | $25.38M 10-Q · filed 2022-11-14 | $32.37M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-06-30 | $10.45M 10-Q · filed 2022-08-15 | $17.65M 10-Q · filed 2022-08-15 | $24.64M derived: sum of 3 quarters · filed 2023-03-14 | $31.30M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-03-31 | $7.20M 10-Q · filed 2022-05-10 | $14.20M derived: sum of 2 quarters · filed 2023-03-14 | $20.86M derived: sum of 3 quarters · filed 2023-03-14 | $27.36M derived: sum of 4 quarters · filed 2023-03-14 |
| 2020-12-31 | $6.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $13.65M derived: sum of 2 quarters · filed 2023-03-14 | $20.16M derived: sum of 3 quarters · filed 2023-03-14 | $26.37M 10-K · filed 2023-03-14 |
| 2020-09-30 | $6.66M 10-Q · filed 2021-11-12 | $13.17M derived: sum of 2 quarters · filed 2021-11-12 | $19.37M 10-Q · filed 2021-11-12 | $25.48M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $6.51M 10-Q · filed 2021-08-11 | $12.71M 10-Q · filed 2021-08-11 | $18.82M derived: sum of 3 quarters · filed 2021-08-11 | $24.50M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $6.21M 10-Q · filed 2021-05-14 | $12.31M derived: sum of 2 quarters · filed 2021-05-14 | $17.99M derived: sum of 3 quarters · filed 2021-05-14 | $23.73M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $6.11M 10-K · filed 2020-03-26 | $11.79M derived: sum of 2 quarters · filed 2020-11-13 | $17.52M derived: sum of 3 quarters · filed 2020-11-13 | $23.40M 10-K · filed 2022-03-15 |
| 2019-09-30 | $5.68M 10-Q · filed 2020-11-13 | $11.42M derived: sum of 2 quarters · filed 2020-11-13 | $17.29M 10-Q · filed 2020-11-13 | $23.26M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $5.74M 10-Q · filed 2020-08-13 | $11.61M 10-Q · filed 2020-08-13 | $17.57M derived: sum of 3 quarters · filed 2020-08-13 | $24.25M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $5.88M 10-Q · filed 2020-05-12 | $11.84M derived: sum of 2 quarters · filed 2020-05-12 | $18.52M derived: sum of 3 quarters · filed 2020-05-12 | $28.48M derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $5.96M 10-K · filed 2020-03-26 | $12.64M derived: sum of 2 quarters · filed 2020-03-26 | $22.60M derived: sum of 3 quarters · filed 2020-03-26 | $32.82M 10-K · filed 2021-03-24 |
| 2018-09-30 | $6.68M 10-K · filed 2020-03-26 | $16.64M derived: sum of 2 quarters · filed 2020-03-26 | $26.86M 10-Q · filed 2019-11-14 | $38.06M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $9.96M 10-K · filed 2020-03-26 | $20.18M 10-Q · filed 2019-08-14 | $31.38M derived: sum of 3 quarters · filed 2020-03-26 | $42.21M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $10.22M 10-K · filed 2020-03-26 | $21.42M derived: sum of 2 quarters · filed 2020-03-26 | $32.25M derived: sum of 3 quarters · filed 2020-03-26 | $44.15M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $11.20M 10-K · filed 2019-03-26 | $22.03M derived: sum of 2 quarters · filed 2019-03-26 | $33.93M derived: sum of 3 quarters · filed 2019-03-26 | $47.15M 10-K · filed 2020-03-26 |
| 2017-09-30 | $10.83M 10-K · filed 2019-03-26 | $22.73M derived: sum of 2 quarters · filed 2019-03-26 | $35.95M 10-Q · filed 2018-11-14 | $48.47M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-06-30 | $11.91M 10-K · filed 2019-03-26 | $25.12M 10-Q · filed 2018-08-14 | $37.65M derived: sum of 3 quarters · filed 2019-03-26 | $51.51M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-03-31 | $13.21M 10-K · filed 2019-03-26 | $25.74M derived: sum of 2 quarters · filed 2019-03-26 | $39.60M derived: sum of 3 quarters · filed 2019-03-26 | $55.04M derived: sum of 4 quarters · filed 2019-03-26 |
| 2016-12-31 | $12.53M 10-K · filed 2018-03-20 | $26.39M derived: sum of 2 quarters · filed 2018-03-20 | $41.83M derived: sum of 3 quarters · filed 2018-03-20 | $57.94M 10-K · filed 2019-03-26 |
| 2016-09-30 | $13.87M 10-K · filed 2018-03-20 | $29.30M derived: sum of 2 quarters · filed 2018-03-20 | $45.41M 10-Q · filed 2017-11-14 | $61.90M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-06-30 | $15.43M 10-K · filed 2018-03-20 | $31.55M 10-Q · filed 2017-08-14 | $48.03M derived: sum of 3 quarters · filed 2018-03-20 | $59.34M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-03-31 | $16.11M 10-K · filed 2018-03-20 | $32.60M derived: sum of 2 quarters · filed 2018-03-20 | $43.91M derived: sum of 3 quarters · filed 2018-03-20 | $54.81M derived: sum of 4 quarters · filed 2018-03-20 |
| 2015-12-31 | $16.48M 10-K · filed 2017-03-16 | $27.80M derived: sum of 2 quarters · filed 2017-03-16 | $38.69M derived: sum of 3 quarters · filed 2017-03-16 | $47.62M 10-K · filed 2018-03-20 |
| 2015-09-30 | $11.31M 10-K · filed 2017-03-16 | $22.21M derived: sum of 2 quarters · filed 2017-03-16 | $31.13M 10-Q · filed 2016-11-14 | $37.16M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $10.90M 10-K · filed 2017-03-16 | $19.82M 10-Q · filed 2016-08-10 | $25.85M derived: sum of 3 quarters · filed 2017-03-16 | $32.08M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $8.92M 10-K · filed 2017-03-16 | $14.95M derived: sum of 2 quarters · filed 2017-03-16 | $21.18M derived: sum of 3 quarters · filed 2017-03-16 | $26.55M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $6.03M 10-K · filed 2016-03-30 | $12.26M derived: sum of 2 quarters · filed 2016-03-30 | $17.62M derived: sum of 3 quarters · filed 2016-03-30 | $23.55M 10-K · filed 2017-03-16 |
| 2014-09-30 | $6.23M 10-K · filed 2016-03-30 | $11.59M derived: sum of 2 quarters · filed 2016-03-30 | $17.52M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $5.36M 10-K · filed 2016-03-30 | $11.29M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | $5.93M 10-K · filed 2016-03-30 | |||
| 2013-12-31 | $19.54M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |